Fenretinide

Generic Name: Fenretinide

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₃NO_₂

CAS Number: 65646-68-6

Unique Ingredient Identifier: 187EJ7QEXL

Background: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Indication: Investigated for use/treatment in macular degeneration.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Fenretinide in Treating Patients With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-05-21

Last Posted Date: 2014-04-11

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 31

Registration Number: NCT00003250

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Recurrent Prostate Cancer

Interventions: Drug: fenretinide
Other: laboratory biomarker analysis

First Posted Date: 2004-04-08

Last Posted Date: 2015-03-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00080899

Locations: 🇺🇸
University of Southern California, Norris, Los Angeles, California, United States

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-02-12

Last Posted Date: 2013-05-15

Lead Sponsor: Cancer Therapeutics Research Group

Target Recruit Count: 50

Registration Number: NCT00077402

Locations: 🇦🇺
Sydney Cancer Centre at Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇦🇺
Sir Charles Gairdner Hospital - Perth, Perth, Western Australia, Australia
🇸🇬
Johns Hopkins Singapore International Medical Centre, Singapore, Singapore

and more 3 locations

Neoadjuvant and Adjuvant Fenretinide Compared With Adjuvant Fenretinide Alone in Treating Patients Who Are Undergoing Surgical Resection For Recurrent Glioblastoma Multiforme

Phase 2

Terminated

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Tumor

Interventions: Drug: fenretinide
Other: pharmacological study
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2004-01-12

Last Posted Date: 2013-01-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00075491

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fenretinide in Treating Patients With Recurrent Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-12-23

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00006080

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 8 locations

Fenretinide in Treating Children With Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Neuroblastoma

Interventions: Drug: fenretinide

First Posted Date: 2003-11-26

Last Posted Date: 2013-02-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00003191

Locations: 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

and more 23 locations

Chemotherapy in Treating Patients With Advanced Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-08-08

Last Posted Date: 2013-04-05

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00011973

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

Combination Chemotherapy in Treating Patients With Solid Tumors

Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-06-06

Last Posted Date: 2013-05-15

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00009932

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Not Applicable

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 71

Registration Number: NCT00017134

Locations: 🇺🇸
CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States
🇺🇸
Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States

and more 32 locations

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

Phase 2

Completed

Conditions: Recurrent Neuroblastoma

Interventions: Drug: fenretinide
Other: pharmacological study

First Posted Date: 2003-01-28

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT00053326

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy